Epidyolex® receives marketing authorization from the EMA for seizures

Written by Sharon Salt, Editor

GW Pharmaceuticals (CA, USA) has announced that the European Commission has approved the marketing authorization of Epidyolex® (cannabidiol) for use as an adjunctive therapy (in conjunction with clobazam) for seizures associated with Lennox–Gastaut syndrome (LGS) or Dravet syndrome in patients 2 years of age and older. “The approval of Epidyolex marks a significant milestone, offering patients and their families the first in a new class of epilepsy medicines and the first and only EMA-approved cannabidiol medicine to treat two severe and life-threatening forms of childhood-onset epilepsy,” commented Justin Gover, Chief Executive Officer at GW Pharmaceuticals. The approval was based on...

To view the full article, please register now for access

It's completely free